FDA warns Pfizer over late reporting of adverse drug events
This article was originally published in Scrip
Executive Summary
The US FDA has issued Pfizer a warning letter principally concerning its failure to report post-marketing adverse drug experiences (ADEs) in a timely fashion, as required under law.